Urology

This article details the use of androgen deprivation therapy in current clinical practice as discussed in an Accord Healthcare-sponsored symposium, delivered as part of the European Association of Urology (EAU) 38th Annual Congress held in Milan, Italy, between 10th–13th March 2023.

Juan Gómez Rivas | Urology Consultant, Hospital Clinico San Carlos, Madrid, Spain; Assistant Professor, Universidad Complutense de Madrid, Spain

Timothy Clinton – Urologic Oncologist and Associate Surgeon, Dana–Farber Cancer Institute and Brigham and Women’s Hospitals, Boston, Massachusetts, USA; Faculty Member, Harvard University, Boston, USA.

Kari Tikkinen – Professor of Urology, Department of Surgery, University of Helsinki, Finland; Consultant Urologic Surgeon at the Department of Urology, Helsinki University Hospital, Finland and the Department of Surgery, South Karelian Central Hospital, Finland

Bhaskar Somani – Professor and Consultant Urological Surgeon, University of Southampton, UK; Clinical Director of South Coast Lithotripter Services, UK; Endourology Lead, University Hospital Southampton, UK

Ben Challacombe |Consultant Urological Surgeon, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, UK. Having spent over 10 years in your current role with Guy’s and St Thomas’, what initially sparked your interest in urology and has pushed you to reach your established position today?

Bladder cancer (BC) is the fourth most common malignancy in males and shows high prevalence and mortality rates worldwide despite improvements in its management.

Testicular seminomas are the most common type of testicular germ cell tumours. It typically affects young males between the ages of 30–55 years. Because of its high sensitivity to chemotherapy and radiotherapy, these tumours have high cure rates.